We enable personalized cancer care
Our solutions provide physicians with precise cancer diagnostics, monitoring, and therapy-decision support.
Oncobit™ DxM is a targeted sequencing approach to assess FFPE tissue of advanced melanoma patients.
Oncobit™ DxM captures:
- mutations in all melanoma-relevant genes
- melanoma-relevant gene rearrangements
- copy number variants (CNV) in a genome-wide manner and chromosomal aneuploidies
- total tumor mutational burden (TMB)
- mutation signatures
- HLA types
- T-cell receptor (TCR) clonality
All findings are annotated with a curated knowledge database of approved and off-label therapies and ongoing clinical trials relevant for the respective patient. Results, suggested therapies and trials are summarized in an automatically generated customized report, providing a precise diagnosis of the tumor as well as therapy decision support.
Oncobit™ LBM is a targeted sequencing approach to assess blood samples of advanced melanoma patients.
Oncobit™ LBM captures:
- mutations in 60 melanoma-relevant genes
- copy number variants (CNV) in melanoma-relevant genes
- HLA types
All findings are annotated with a curated knowledge database to identify genomic alterations. Assessing circulating tumor-derived DNA (ctDNA) isolated from the blood of cancer patients, this method is minimally invasive and provides a comprehensive characterization of cancer and therapy resistance markers in the patient’s blood.
Oncobit™ PM allows us to provide highly sensitive monitoring of specific molecular alterations with a short turnaround time. The number and type of alterations evaluated is customized for each patient.
Similar to Oncobit™ LBM, Oncobit™ PM is a minimally invasive liquid biopsy assay. Oncobit PM represents a tool for personalized monitoring of cancer patients of all types of solid tumors.